Probability of clinical and immunologic complications for 194 WAS patients who received HCT. (A) Percentage of patients who developed any complication (graft failure/rejection, acute GVHD grade 3 or 4, extensive cGVHD, severe infections, autoimmune manifestations, tumors, and post-HCT sequelae) up to 5 years after HCT, according to donor type. (B) Percentage of patients who developed any complication up to 5 years after HCT, according to clinical status (measured by clinical score) at the time of HCT. *P < .05. ****P < .001